Smokers Having Activating EGFR Mutant Non-Small Cell Lung Cancer Might Benefit from EGFR-TKI Treatment – Single-Center Experience

Median PFS was 21 months for patients using EGFR TKI in the first-line (35patients), and 13 months in the second-line setting (11 patients).CONCLUSIONThere were no statistically significant PFS differences between the smoker and non-smoker groups.Smokers should be tested for EGFR mutations, as some patients may benefit from EGFR TKI treatmentfor longer than reported in the literature.

📌 3 Key Takeaways

🎯

Objective & Hypothesis:OBJECTIVEThis study aims to evaluate the predictive impacts of cigarette smoking on treatment outcomes of EGFRtyrosine kinase inhibitors (TKIs) in Non-Small Cell Lung Cancer (NSCLC) patients with activatingEGFR mutations.METHODSWe retrospectively evaluated the data of 46 patients with metastatic NSCLC (adenocarcinoma) andEGFR mutation (exon 19 deletion, exon 21 mutation, and exon 18 activating mutation) treated withEGFR-TKI between 2012 and 2017.RESULTSMedian age was 61 (range 30-80), and 56.5% (26/46) was female.

📊

Key Findings & Data:Median follow-up was 39 months.

💡

Conclusion & Impact:Median PFS was 21 months for patients using EGFR TKI in the first-line (35patients), and 13 months in the second-line setting (11 patients).CONCLUSIONThere were no statistically significant PFS differences between the smoker and non-smoker groups.Smokers should be tested for EGFR mutations, as some patients may benefit from EGFR TKI treatmentfor longer than reported in the literature.

🔬Design:Research Article

📍Scope:2012 Verileri

⚙️Variables:Domain Parameters

Abstract

OBJECTIVEThis study aims to evaluate the predictive impacts of cigarette smoking on treatment outcomes of EGFRtyrosine kinase inhibitors (TKIs) in Non-Small Cell Lung Cancer (NSCLC) patients with activatingEGFR mutations.METHODSWe retrospectively evaluated the data of 46 patients with metastatic NSCLC (adenocarcinoma) andEGFR mutation (exon 19 deletion, exon 21 mutation, and exon 18 activating mutation) treated withEGFR-TKI between 2012 and 2017.RESULTSMedian age was 61 (range 30-80), and 56.5% (26/46) was female. Median follow-up was 39 months. Therate of smoking was 41.3% (19/46). The EGFR mutations were present in the patients, exon 19 deletionin 29 patients (64%), exon 21 mutation in 13 patients (28%) and exon 18 activating mutations in fourpatients (8%). Progression-free survival (PFS) was 21 months in smokers, whereas it was 25 months innon-smokers (p=0.330). Median PFS was 21 months for patients using EGFR TKI in the first-line (35patients), and 13 months in the second-line setting (11 patients).CONCLUSIONThere were no statistically significant PFS differences between the smoker and non-smoker groups.Smokers should be tested for EGFR mutations, as some patients may benefit from EGFR TKI treatmentfor longer than reported in the literature.

🔖

Cite This Article

YUMUK, P. F., ERCELEP, Ö., DANE, F., ALAN, Ö., TELLİ, T. A., HASANOV, R., ŞİMŞEK, E. T., BABACAN, N. A., KAYA, S., KAYA, H. (2022). Smokers Having Activating EGFR Mutant Non-Small Cell Lung Cancer Might Benefit from EGFR-TKI Treatment – Single-Center Experience. Türk Onkoloji Dergisi, Cilt: 35 - Sayı: 3, 334–339. https://ajindex.com/articles/639152

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (12)

Wynder EL, Graham EA. Landmark article May 27, 1950: Tobacco Smoking as a possible etiologic factor in bronchiogenic carcinoma. A study of six hundred and eighty-four proved cases. By Ernest L. Wynder and Evarts A. Graham. JAMA 1985
253(20):2986–94. 2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005
74–108. 3. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers--a different disease. Nat Rev Cancer.2007
7(10):778–90. 4. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009
361(10):958–67. 5. Zhang YL, Yuan JQ, Wang KF, Fu XH, Han XR, Threapleton D, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget 2016
7(48):78985–93. 6. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005
339–46. 7. Ahn MJ, Park BB, Ahn JS, Kim SW, Kim HT, Lee JS, et al. Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer? Clin Cancer Res 2008
14(12):3860– 6. 8. Tomizawa Y, Iijima H, Sunaga N, Sato K, Takise A, Otani Y, et al. Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with nonesmall cell lung cancer. Clin Cancer Res 2005
6816–22. 9. Hsieh RK, Lim KH, Kuo HT, Tzen CY, Huang MJ. Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer. Chest 2005
128(1):317–21. 10. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation- positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011
Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012
Wu YL, Zhou C, Liam CK, Wu G, Liu X, Zhong Z, et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non